

References

1. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. *Rev Neurol*. 2020 May 1;70(9):311-322. ([HERE](#))
2. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. *Lancet Respir Med*. 2021 May;9(5):533-544. ([HERE](#))
3. Caldwell M, Boruah AP, Thakur KT. Acute neurologic emerging flaviviruses. *Ther Adv Infect Dis*. 2022 Jun 13;9:20499361221102664. ([HERE](#))
4. Ganguli S, Chavali PL. Intrauterine Viral Infections: Impact of Inflammation on Fetal Neurodevelopment. *Front Neurosci*. 2021 Nov 10;15:771557. ([HERE](#)).
5. Abboud H, Abboud FZ, Kharbouch H, et al. COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. *World Neurosurg*. 2020 Aug;140:49-53. ([HERE](#))
6. Andalib S, Biller J, Di Napoli M, et al. Peripheral Nervous System Manifestations Associated with COVID-19. *Curr Neurol Neurosci Rep*. 2021 Feb 14;21(3):9. ([HERE](#))
7. Costas-Carrera A, Sánchez-Rodríguez MM, Cañizares S, et al. Neuropsychological functioning in post-ICU patients after severe COVID-19 infection: The role of cognitive reserve. *Brain Behav Immun Health*. 2022 May;21:100425. PMID: 35156065 ([HERE](#))
8. Pink I, Welte T. Häufigkeit, Spektrum und Risikofaktoren von Long-COVID [Frequency, spectrum and risk factors of long COVID]. *Inn Med (Heidelb)*. 2022 Aug;63(8):813-818. German ([Translated via Google Translate to English](#)) – ([HERE](#))
9. Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J. Inf. Secur*. 2020;81(6):e4–e6. ([HERE](#))
10. Group TWCftCS. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. *JAMA*. 2021;325(15):1525–1534. ([HERE](#))
11. Jennings G, Monaghan A, Xue F, et al. A Systematic Review of Persistent Symptoms and Residual Abnormal Functioning following Acute COVID-19: Ongoing Symptomatic Phase vs. Post-COVID-19 Syndrome. *J Clin Med*. 2021 Dec 16;10(24):5913. ([HERE](#))
12. Bach K. Is Long COVID worsening labor shortage? Brookings Report, Jan 11 2022 ([HERE](#))
13. Yomogida K, Zhu S, Rubino F, et al. Post-Acute Sequelae of SARSCoV-2 Infection Among Adults Aged ≥18 Years — Long Beach, California, April 1–December 10, 2020. *MMWR. Morbidity and Mortality Weekly Report*. 2021. pp. 1274–1277. ([HERE](#))
14. Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Netw Open*. 2021;4: e2128568. ([HERE](#))
15. Chen C, Hauptert SR, Zimmermann L, et al. Shi X, Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis*. 2022. doi:10.1093/infdis/jiac136 ([HERE](#))
16. Ahmed JO, Ahmad SA, Hassan MN, et al. Post COVID-19 neurological complications; a meta-analysis. *Ann Med Surg (Lond)*. 2022 Apr;76:103440. PMID: 35261766 ([HERE](#))
17. Dhaeze T, Tremblay L, Lachance C, et al. CD70 defines a subset of proinflammatory and CNS-pathogenic T_H1/T_H17 lymphocytes and is overexpressed in multiple sclerosis. *Cell Mol Immunol*. 2019 Jul;16(7):652-665. ([HERE](#))
18. Estiasari R, Maharani K, Octaviana F, et al. Encephalomyelitis associated with coronavirus disease 2019: a case report. *J Med Case Rep*. 2022 Aug 23;16(1):329. ([HERE](#))

19. Abenza Abildúa M.J., Atienza S., Carvalho Monteiro G., et al. Encephalopathy and encephalitis during acute SARS-CoV-2 infection. Spanish Society of Neurology COVID-19 Registry. *Neurologia (Engl Ed)* 2021;36:127–134. ([HERE](#))
20. Bholá S, Trisal J, Thakur V, et al. Neurological toll of COVID-19. *Neurol Sci.* 2022 Apr;43(4):2171-2186. ([HERE](#))
21. Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. *BMJ.* 2021 Jul 26;374:n1648. ([HERE](#))
22. Cristillo V, Pilotto A, Piccinelli SC, et al. Predictors of "brain fog" 1 year after COVID-19 disease. *Neurol Sci.* 2022 Aug 5:1–3. ([HERE](#))
23. Romero-Ortuno R, Jennings G, Xue F, et al. Predictors of Submaximal Exercise Test Attainment in Adults Reporting Long COVID Symptoms. *Journal of Clinical Medicine.* 2022; 11(9):2376. ([HERE](#))
24. Townsend L, Dyer AH, Jones K, et al. et al. (2020) Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLoS ONE* 15(11): e0240784. ([HERE](#))
25. Jennings G, Monaghan A, Xue F, et al. Comprehensive Clinical Characterisation of Brain Fog in Adults Reporting Long COVID Symptoms. *J Clin Med.* 2022 Jun 15;11(12):3440. ([HERE](#))
26. Saif DS, Ibrahim RA, Eltabl MA. Prevalence of peripheral neuropathy and myopathy in patients post-COVID-19 infection. *Int J Rheum Dis.* 2022 Aug 1. Epub ahead of print. PMID: 35915515. ([HERE](#))
27. Lauria A, Carfi A, Benvenuto F, et al. Gemelli Against COVID-19 Post-acute Care Study Group. Neuropsychological Measures of Long COVID-19 Fog in Older Subjects. *Clin Geriatr Med.* 2022 Aug;38(3):593-603. ([HERE](#))
28. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine.* 2021 Aug;38:101019. ([HERE](#))
29. Ledford H. Long-COVID treatments: why the world is still waiting. *Nature.* 2022 Aug;608(7922):258-260. ([HERE](#))
30. Doran C, Elsinga J, Fokkema A, et al. Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao. *PLoS Negl Trop Dis.* 2022 Mar 1;16(3):e0010142. ([HERE](#))
31. Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. *Nat Commun.* 2022 Aug 30;13(1):5104. ([HERE](#))
32. Augustin M., Schommers P., Stecher M., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *Lancet Reg. Health - Eur.* 2021;6 ([HERE](#))
33. Lu Y., Li X., Geng D., et al. Cerebral micro-structural changes in COVID-19 patients – an MRI-based 3-month follow-up study. *EClinicalMedicine.* 2020;25 ([HERE](#))
34. Nguyen N.N., Hoang V.T., Lagier J.-C., Raoult D., Gautret P. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. *Clin. Microbiol. Infect.* 2021;27(6):931–932. ([HERE](#))
35. Orrù G., Bertelloni D., Diolaiuti F., et al. Long-COVID syndrome? A study on the persistence of neurological, psychological and physiological symptoms. *Healthcare.* 2021;9(5):575. ([HERE](#))

36. Taylor R.R., Trivedi B., Patel N., et al. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. *Clin. Med.* 2021;21(4):e384–e391. ([HERE](#))
37. Menges D., Ballouz T., Anagnostopoulos A., et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. *PLoS One.* 2021;16(7) ([HERE](#))
38. Simani L., Ramezani M., Darazam I.A., et al. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. *J. Neuro-Oncol.* 2021;27(1):154–159. ([HERE](#))
39. Frontera J.A., Yang D., Lewis A., et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. *J. Neurol. Sci.* 2021;426 ([HERE](#))
40. National Institute for Health and Care Excellence (NICE). (2020) COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 NICE Guideline; c2020. ([HERE](#))
41. Vink M, Vink-Niese F. Is It Useful to Question the Recovery Behaviour of Patients with ME/CFS or Long COVID? *Healthcare (Basel)*. 2022 Feb 18;10(2):392. ([HERE](#))
42. Bellan M., Soddu D., Balbo P.E., et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. *JAMA Netw. Open.* 2021;4(1) ([HERE](#))
43. Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet (London, England)* 2021;397(10270):220–232. ([HERE](#))
44. Ugurlu B.N., Akdogan O., Yilmaz Y.A., et al. Quantitative evaluation and progress of olfactory dysfunction in COVID-19. *Eur. Arch. Otorhinolaryngol.* 2021;278(7):2363–2369. ([HERE](#))
45. O'Byrne L, Webster KE, MacKeith S, et al. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. *Cochrane Database Syst Rev.* 2022 Sep 5;9:CD013876. ([HERE](#))
46. NIH Clinicaltrials.gov Long COVID Studies ([HERE](#))